Michèle Cavo

Active 1991–2025

Also published as
Michele Cavo
321
Papers
61,112
Citations
120
h-index
307
i10-index

Citations

Citations per year for Michèle Cavo1948: 3 citations1979: 3 citations1984: 1 citations1988: 3 citations1990: 3 citations1992: 2 citations1993: 3 citations1994: 6 citations1995: 5 citations1996: 10 citations1997: 10 citations1998: 14 citations1999: 10 citations2000: 21 citations2001: 16 citations2002: 27 citations2003: 60 citations2004: 46 citations2005: 49 citations2006: 44 citations2007: 58 citations2008: 62 citations2009: 112 citations2010: 127 citations2011: 216 citations2012: 158 citations2013: 232 citations2014: 309 citations2015: 335 citations2016: 375 citations2017: 426 citations2018: 335 citations2019: 1,698 citations2020: 2,083 citations2021: 2,445 citations2022: 2,083 citations2023: 1,605 citations2024: 2,915 citations2025: 1,342 citations2026: 43 citations1949–1978: no citations, so these years are not shown1980–1983: no citations, so these years are not shown1985–1987: no citations, so these years are not shown1989: no citations, so this year is not shown1991: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,765 citing papers, 23.2% of this breakdownItaly: 1,285 citing papers, 7.9% of this breakdownGermany: 1,031 citing papers, 6.4% of this breakdownChina: 1,011 citing papers, 6.2% of this breakdownUnited Kingdom: 950 citing papers, 5.9% of this breakdownFrance: 901 citing papers, 5.6% of this breakdownSpain: 819 citing papers, 5% of this breakdownNetherlands: 542 citing papers, 3.3% of this breakdownCanada: 507 citing papers, 3.1% of this breakdownAustralia: 428 citing papers, 2.6% of this breakdownGreece: 408 citing papers, 2.5% of this breakdownBelgium: 352 citing papers, 2.2% of this breakdown
0%23.2%Other 26.1%

Fields

  • Medicine80.7%
  • Biochemistry, Genetics and Molecular Biology13.8%
  • Immunology and Microbiology2.6%
  • Computer Science0.5%
  • Engineering0.4%
  • Nursing0.4%
  • Other1.6%

Topics

  • Multiple Myeloma Research and Treatments17%
  • Protein Degradation and Inhibitors6.7%
  • CAR-T cell therapy research5.8%
  • Peptidase Inhibition and Analysis3.9%
  • Amyloidosis: Diagnosis, Treatment, Outcomes2.8%
  • Cancer Treatment and Pharmacology2.6%
  • Other61.2%

Coauthors

All papers

Open in search
  1. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2021 cited by 2,424

  2. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Wen-Ming Chen, Michèle Cavo, Jean‐Luc Harousseau, Suzanne Lentzsch, Jens Hillengaß, Antonio Palumbo, Alberto Órfão, S. Vincent Rajkumar, Jesús F. San Miguel, Hervé Avet‐Loiseau - The Lancet Oncology 2016 cited by 2,995

  3. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Robert A. Kyle, Kenneth C. Anderson, Brian G.M. Durie, Jesús F. San Miguel - The Lancet Oncology 2014 cited by 4,869

  4. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Carolyn C. Jackson, Kaitlyn Connors, Katherine Li, Enrique Zudaire, Diana Chen, Jane Gilbert, Tzu‐Min Yeh, Sarah Nagle, Erika Florendo, Lida Pacaud, Nitin Patel, Simon J. Harrison, Hermann Einsele - New England Journal of Medicine 2023 cited by 733

  5. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2023 cited by 705

  6. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Philippe Moreau - Journal of Clinical Oncology 2015 cited by 2,178

  7. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sarah Lonergan, Tahamtan Ahmadi, Yanfang Liu, Jianping Wang, Diego Vieyra, Emilie M.J. van Brummelen, Véronique Vanquickelberghe, Anna Sitthi-Amorn, Carla J. de Boer, Robin Carson, Paula Rodríguez‐Otero, Joan Bladé, Philippe Moreau - New England Journal of Medicine 2023 cited by 515

  8. Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up.

    Authors: , , , , , , , , , , , , , , , , - Annals of Oncology 2021 cited by 820

  9. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Pieter Sonneveld - Journal of Clinical Oncology 2022 cited by 407

  10. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2023 cited by 178

  11. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Pieter Sonneveld, Hermann Einsele, Philippe Moreau - Leukemia 2022 cited by 240

  12. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kim Kihyun, Gracia Martınez, Min Chang‐Ki, Luděk Pour, Xavier Leleu, Albert Oriol, Koh Youngil, Kenshi Suzuki, Tom Martin, Hang Quach, Andrew Lim, Helen Crowther, Hanlon Sia, Cyrille Hulin, Mohamad Mohty, Gábor Mikala, Zsolt Nagy, Marta Reinoso Segura, Laura Rosiñol, Münci Yağcı, Mehmet Turgut, Mamta Garg, Gurdeep Parmar, Brad Augustson, Nelson Castro, Edvan de Queiroz Crusoé, Tomáš Pika, Sosana Delimpasi, Kenichi Ishizawa, Anup George, Т. С. Константинова, Javier de la Rubia, Kim Sung-Hyun, Ângelo Maiolino, Tony Reiman, Richard LeBlanc, Shigeki Ito, Junji Tanaka, А. С. Лучинин, I. V. Kryuchkova, Joaquín Martínez‐López, Jesse Shustik, Lionel Karlin, Anargyros Symeonidis, Miklós Egyed, Mario Petrini, Michèle Cavo, Michihiro Uchiyama, Hilary Blacklock, Mutlu Arat, James E. Griffin, Hannah Hunter, Tonda Buck, Αchilles Anagnostopoulos, Κωνσταντίνος Κωνσταντόπουλος, Tamás Masszi, Sara Bringhen, Barbara Gamberi, Yawara Kawano, Kim Jin Seok, Hakan Özdoğu, Fahir Özkalemkaş - The Lancet 2021 cited by 380

  13. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jeffrey Shang-Yi Huang, Jiří Minařík, Michèle Cavo, H. Miles Prince, Sandrine Macé, Kathryn P. Corzo, Frank Campana, Solenn Le-Guennec, Franck Dubin, Kenneth C. Anderson, Simon J. Harrison, Wojciech Janowski, Ian Kerridge, Andrew Spencer, Michel Delforge, Karel Fostier, Philip Vlummens, Ka Lung Wu, Richard LeBlanc, Michel Pavic, Michaël Sébag, Roman Hájek, Vladimír Maisnar, Luděk Pour, Henrik Gregersen, Lotfi Benbouker, Denis Caillot, Martine Escoffre‐Barbe, Thierry Façon, Laurent Frenzel, Cyrille Hulin, Lionel Karlin, Brigitte Kolb, Brigitte Pegourié, Aurore Perrot, Mourad Tiab, Laure Vincent, Dietger Niederwieser, Αchilles Anagnostopoulos, Sosana Delimpasi, Marie‐Christine Kyrtsonis, Anargyros Symeonidis, Árpád Illés, Gábor Mikala, Zsolt Nagy, Sara Bringen, Paolo Corradini, Fabio Ciceri, Roberto M. Lemoli, Anna Marina Liberati, Chiara Nozzoli, Renato Zambello, Shinsuke Iida, Takashi Ikeda, Satoshi Iyama, Morio Matsumoto, Chihiro Shimazaki, Kazutaka Sunami, Kenshi Suzuki, Michihiro Uchiyama, Youngil Koh, Kihyun Kım, Jae Hoon Lee, Chang‐Ki Min, Hillary Blacklock, Hugh J. B. Goodman, Annette Neylon, David Simpson, Sebastian Grosicki, Artur Jurczyszyn and 30 more - The Lancet 2019 cited by 636

  14. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2017 cited by 984

  15. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jelena Bila, Mario Boccadoro, Michèle Cavo, Javier de la Rubia Comos, Sosana Delimpasi, Meletios Α. Dimopoulos, Chantal Doyen, Dominik Dytfeld, Monika Engelhardt, Thierry Façon, Roberto Foà, Hartmut Goldschmidt, Sebastian Grosicki, Roman Hájek, Güner Hayri Özsan, Cyrille Hulin, Brian Iversen, Lionel Karlin, Eirini Katodritou, Stefan Knop, Marie‐Christine Kyrtsonis, Juan José Lahuerta, Xavier Leleu, Carmen Martínez Chamorro, María-Victoria Mateos Manteca, Nathalie Meuleman, Monique C. Minnema, Philippe Moreau, Massino Offidani, Albert Oriol Rocafiguera, Mustafa Pehlıvan, Luděk Pour, Henk Roerdink, Laura Rosinol Dacsh, Hans Salwender, Pieter Sonneveld, Anargyros Symeonidis, Charlotte Toftmann Hansen, Tülin Tuğlular, Ali Ünal, Philip Vlummens, Filiz Vural, Ka Lung Wu, Sonja Zweegman - The Lancet Oncology 2021 cited by 327

  16. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Baldeep Wirk, Matthew T. Drake, Michèle Cavo, Juan José Lahuerta, Suzanne Lentzsch - The Lancet Oncology 2019 cited by 496

  17. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2020 cited by 404

  18. Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Simon McNamara, Xiangdong Zhou, Maureen Nichols, Eric Lewis, Rachel Rogers, Hena Baig, Lydia Eccersley, Sumita Roy–Ghanta, Joanna Opalińska, María-Victoria Mateos - New England Journal of Medicine 2024 cited by 166

  19. Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2024 cited by 151

  20. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jelena Bila, Eirini Katodritou, Hanna Oliynyk, Sybiryna Korenkova, Jeevan Kumar, Sundar Jagannath, Philippe Moreau, Moshe Levy, Darrell White, Moshe E. Gatt, Thierry Façon, María‐Victoria Mateos, Michèle Cavo, Donna Reece, Larry D. Anderson, Jean-Richard Saint-Martin, Jacqueline Jeha, Anita Joshi, Yi Chai, Lingling Li, Vishnuvardhan Peddagali, Melina Arazy, Jatin J. Shah, Sharon Shacham, Michael Kauffman, Meletios Α. Dimopoulos, Paul G. Richardson, Sosana Delimpasi - The Lancet 2020 cited by 324

  21. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2016 cited by 1,054

  22. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2021 cited by 244

  23. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2019 cited by 438

  24. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Achilleas Anagnostopoulos, Larry D. Anderson, Pekka Anttila, Carla Araujo, Carlos Arce‐Lara, Yıldız Aydın, Supratik Basu, Ramakrishna Battini, Thaddeus Beeker, Lotfi Benboubker, Dina Ben‐Yehuda, Joan Bladé, Igor Wolfgang Blau, Ralph V. Boccia, Lillian Burke, Peter D. Byeff, Nicola Cascavilla, Michèle Cavo, Andrew Chantry, Yen Charles, Arvind Chaudhry, Alessandro Corso, Mark Coyne, Felipe de Arriba, Sosana Delimpasi, Pierre Desjardins, Binod Dhakal, Paolo Di Bartolomeo, Francesco Di Raimondo, Jan Dürig, Monika Engelhardt, Martine Escoffre‐Barbe, Graça Esteves, Max Flogegård, Nashat Gabrail, Barbara Gamberi, Mitchell Garrison, Julie Gay, Heinz Gisslinger, Hartmut Goldschmidt, Cristina Gonçalves, Laurent Gressot, Sebastian Grosicki, Wahid T. Hanna, Patrick Hayden, Maria Manuela Henriques Bernardo, Róbert Hermann, Viran Holden, Kirsti Honkalehto, Marianne Huben, John Huffman, Hannah Hunter, Marek Hus, Madan Jagasia, Sundar Jagganath, Murali Janakiram, Ishmael Jaiyesimi, Matthew Jenner, Cristina João, Peter Johnson, Artur Jurcyszyn, Sevgi Kalayoğlu Beşışık, Suman Kambhampati, Abraham S. Kanate, Ìhsan Karadoǧan, Ali Khojasteh, Dean Kirkel, Mieczysław Komarnicki, Maria‐Theresa Krauth, Phillip Kuriakose and 65 more - The Lancet Oncology 2019 cited by 385